Overall, the kinome-wide RNAi screen identified the PI3K pathway to be involved in HDAC8 inhibitor-mediated anti-neuroblastoma effects and identified additional druggable RTKs, such as ERBB2 and ALK, as targets to sensitize neuroblastoma to HDAC8 inhibitor treatment. This evidence concerns the gene ALK and neuroblastoma.